shop now
clinical laboratory standards institute logo

 

About CLSI

 

Share Your Comments on New and Revised Standard Documents

Help shape the standards that impact your day-to-day work.

To preserve the integrity of standards developed through the CLSI consensus process, we seek input from the public on our in-process drafts before they are approved for publication. Opening the dialogue to CLSI members and non-members alike, we encourage your involvement in the final shaping of our documents to ensure that all interested parties are given a voice.

General Information

Comments related to CLSI draft documents shall be made in writing using the comment table form and shall be submitted no later than the comment deadline indicated above. Comments, as well as requests for a copy of the document, should be submitted via e-mail to standard@clsi.org or by fax to 610.688.0700.

Documents for Review and Comment

EP33 (Proposed Draft)Use of Delta Checks in the Clinical Laboratory. This guideline provides approaches for selecting tests for use in delta checks, establishing delta check limits and rules for comparing them to previous results, establishing delta checks in the laboratory information system, investigating samples with delta check alerts, and processes for laboratories to evaluate the effectiveness of their delta check systems.

This draft document is available to the public for review and comment for 60 days (November 13, 2014 to January 12, 2015). This review and comment period helps ensure that consensus is achieved so that approved consensus documents can be distributed for use in the health care community. At the end of the 60-day review and comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate. CLSI greatly appreciates your valuable feedback.

GP47(Proposed Draft)Management of Critical-and Significant-Risk Results; Draft Guideline. This document provides current best practice recommendations for developing and implementing a policy and procedures for the identification, reporting, and management of critical- and significant-risk laboratory results. Emphasis is placed on management responsibilities such as development of the policy, the process, job descriptions, and monitoring systems that ensure effective reporting and compliance with regulatory requirements.

This draft document is available to the public for review and comment for 60 days (October 27 to December 26). This review and comment period helps ensure that consensus is achieved so that approved consensus documents can be distributed for use in the health care community. At the end of the 60-day review and comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate. CLSI greatly appreciates your valuable feedback.

MM21 (Proposed Draft)Genomic Copy Number Microarrays for Constitutional Genetic and Oncology Applications. This document provides recommendations for validation, performance, and interpretation of nucleic acid microarrays used for cytogenetic applications to measure copy number imbalances and loss of heterozygosity. Both constitutional and oncology applications are addressed.

This draft document is available to the public for review and comment for 60 days (November 13, 2014 to January 12, 2015). This review and comment period helps ensure that consensus is achieved so that approved consensus documents can be distributed for use in the health care community. At the end of the 60-day review and comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate. CLSI greatly appreciates your valuable feedback.

Please note draft CLSI documents are available only for the purposes of review and comment, and are not to be reproduced or circulated for any other reason. Draft documents have not completed the consensus review process, and therefore, shall not be used for any clinical purposes or to satisfy regulatory or accreditation requirements. They should not to be considered either final or published and may not be quoted or referenced.

 

Did You Know?

CLSI distributes more than
75,000 standards and guidelines per year, worldwide.

Login

Register | Lost your password?